Background. Clinical trials of intracoronary injection of bone marrow-derived stem cells (BMCs) in patients with acute myocardial infarction (AMI) have revealed promising but variable and modest results. One of the reasons underlying this situation may be the unstandardized preparation of BMCs.
Introduction
Clinical trials of intracoronary injection of bone marrow-derived stem cells (BMCs) in patients with acute myocardial infarction (AMI) have revealed promising results. However, improved left ventricular ejection fraction (LVEF) and left ventricular remodeling were observed in most but not all studies. Moreover, the extent of improvement was variable between the trials and the benefit of cell therapy with BMCs was modest. One reason underlying the variable and modest improvement of cardiac function by cell therapy may be related to the unstandardized preparation of BMCs. Serum or plasma, which in some trials was used to provide a suitable physiological environment for BMCs, was reported to induce clotting of the cell product. Similarly heparin, used to prevent coagulation during cell preparation in many clinical trials, has recently been shown to affect the survival and functionality of BMCs. Therefore, the objective of this systematic review and meta-analysis is to explore whether the usage of serum or plasma, heparin and steps of washout during cell preparation may have influenced the results of previous trials.
Methods

Search strategy
We searched MEDLINE for studies of BMCs transplantation in patients with acute myocardial infarction by November 2015 using the following terms: "randomized controlled trials"; "cell therapy"; "stem cells"; "progenitor cells"; "precursor cells"; "bone marrow cells"; "mononuclear cells"; "cell transplantation"; "coronary artery disease"; "myocardial infarction"; "acute myocardial infarction"; and "myocardial ischemia".
Study selection
Since this was a study for exploring the methodology of cell transplantation, we prepared relatively strict criteria to avoid disturbance caused by different study design. Clinical trials were included if they 1) were randomized controlled clinical trials; 2) were conducted on patients with acute myocardial infarction who accepted primary percutaneous coronary intervention (PCI); 3) were using BMCs for cell transplantation; 4) were conducting cell therapy by injecting BMCs into the infarct-related coronary artery; 5) were providing a standard therapy for patients in both control and intervention group; 6) provided a detailed description of cell preparation; and if (7) the ratio of loss to follow-up was < 20%. Only articles published in English were included. We used mean and standard deviation for statistical analysis, so studies reporting data as median and range were not included.
Data extraction
Two investigators independently screened all the titles and abstracts to include studies that met our inclusion criteria, and extracted the data from the papers. When there were disagreements, a third investigator was involved. Inclusion criteria or data would be reviewed and discussed until final decisions were made.
The cardiac outcome measures included changes in LVEF, infarct size (IS), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). The clinical outcome measures from follow-ups included cardiac mortality, all-cause mortality, reinfarction, target-vessel restenosis, all-vessel restenosis, Data processing was done using the methods described in the Cochrane handbook when needed. For studies with more than one intervention arms, with different doses of BMCs or different time for intervention, outcome measures data was combined. For studies that did not report changes in outcome measures between baseline and follow-up, the mean differences and standard deviations were calculated using data from a reference study with presented mean and standard deviation for baseline and final measures as well as for changes from the baseline.
Data analysis
Statistical analyses were performed with Cochrane RevMan v. 5.2.11 (Cochrane, London, UK), and the results were expressed as weighted mean differences for continuous outcomes with 95% confidence intervals (CIs). Data was pooled by a random effects model. Because of low incidence of clinical cardiovascular events during followup and low heterogeneity, Peto OR was applied to obtain an overall estimate of the odds ratio for clinical outcomes, assuming fixed effects. Heterogeneity was analyzed with the I 2 statistic, and was defined as low (25%-50%), intermediate (50%-75%), or high (>75%). The p-values <0.05 (2-sided) were considered as statistically significant. Funnel plots were constructed to explore publication bias.
Quality assessment
The criteria established by Juni et al. were used to assess the quality of studies included, which were all randomized controlled clinical trials.
1
Subgroup analysis for methodological exploration
To determine whether one particular procedure of cell preparation may impact the outcomes, subgroup analyses were conducted based on 1) the supplement of serum or plasma to the cell suspension or not; 2) the use of heparin in the cell suspension or not ('use' was defined as mixing BMCs with heparin during cell preparation); 3) cell washout or not after mixing with heparin during cell preparation.
Results
Search results
The initial search retrieved 1,126 reports with our search strategy. The majority of reports were excluded [3] Quyyumi et al., 2011 [44] Srimahachota et al., 2011 [6] Sürder et al., 2013 [7] Subtotal (95% Cl) Heterogeneity: τ 2 = 0.00; χ 2 = 2.00, df = 3 (p = 0.57); I 2 = 0% Test for overall effect: Z = 0.44 (p = 0.66)
non-serum/plasma
Ge et al., 2006 [8] Lipiec et al., 2009 [9] Cao et al., 2009 [10] Wöhrle et al., 2010 [11] Roncalli et al., 2011 [12] San Roman et al., 2015 [13] Subtotal (95% Cl) Heterogeneity: τ due to other types of study subjects (like chronic heart failure or granulocyte-colony stimulating factor treatment), wrong language, because they were reviews, or were regarded irrelevant on the basis of title and abstract. Full texts of 69 reports were thoroughly analyzed, and 36 reports were further excluded as being not randomized controlled trials, unmatched cell therapy approaches (like intramyocardial injection), a substudy, multiple publications, or without relevant outcomes. Two studies were excluded after full text analysis on account of an incomplete description of cell collection and preparation. One study was omitted because of a high percentage of loss to followup. Another study was excluded from this meta-analysis, because every patient in the cell therapy group received BMCs transplantation (or placebo) twice. The remaining 29 reports (24 clinical trials and 1,728 patients) were eventually included in this meta-analysis. All studies reported LVEF before and after cell transplantation in patients from both the cell therapy and control group, with or without other cardiac parameters and clinical outcomes.
Study characteristics
The median follow-up duration was 13 months (range: 3-61 months) and the median sample size was 72 patients (range: 10-204 patients). Only 7 (29.2%) studies included patients with acute anterior myocardial infarction, and the other studies were nonselective about the infarction segment. Based on the mean range of time from the onset of symptoms to PCI, the majority of patients underwent primary PCI in 24 h, while 3 studies did not give this data in their reports. Most patients cell therapy arm received cell transplantation within 7 days after AMI. Several imaging modalities were involved in these studies, including Fig. 2 . Forest plot of the subgroup analysis of Peto OR in all-cause mortality among the trials using serum/plasma as a supplement for cell suspension or other supplements during BMCs preparation (the outcome was statistically in favor of non-use of serum/plasma for cell preparation) [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
serum/plasma
Schächinger et al., 2006 [14] Janssens et al., 2006 [15] Lunde et al., 2006 [3] Huikuri et al., 2008 [16] Grajek et al., 2010 [17] Srimahachota et al., 2011 [6] Quyyumi et al., 2011 [5] Sürder et al., 2013 [7] Subtotal (95% Cl) Total events Heterogeneity: χ 2 = 3.89, df = 5 (p = 0.57); I 2 = 0% Test for overall effect: Z = 1.91 (p = 0.06) [18] Go et al., 2006 [8] Cao et al., 2009 [10] Plewka et al., 2009 [21] Nogueira et al., 2009 [22] Silva et al., 2009 [23] Wöhrle et al., 2010 [11] Traverse et al., 2010 [24] Colombo et al., 2011 [25] Hirsch et al., 2011 [26] Roncalli et al., 2011 [12] Traverse et al., 2010 [28] Traverse et al., 2011 [29] San Roman et al., [3] Cao et al., 2009 [10] Wöhrle et al., 2010 [11] Quyyumi et al., 2011 [5] Roncalli et al., 2011 [12] Sürder et al., 2013 [7] San Roman et al., 2015 [13] Subtotal (95% Cl) Heterogeneity: τ 2 = 2.32; χ 2 = 21.55, df = 6 (p = 0.001); I 2 = 72% Test for overall effect: Z = 0.99 (p = 0.32)
others Wollert et al., 2004
non-heparin
Ge et al., 2006 [8] Lipiec et al., 2009 [9] Srimahachota et al., 2011 [6] Subtotal (95% Cl) Heterogeneity: τ 2 = 0.00; χ 2 = 0.07, df = 2 (p = 0. [3] Huikuri et al., 2008 [16] Grajek et al., 2010 [17] Wöhrle et al., 2010 [11] Hirsch et al., 2011 [26] San Roman et al. [18] Schächinger et al., 2006 [14] Cao et al., 2009 [10] Traverse et al., 2010 [28] Roncalli et al., 2011 [12] Quyyumi et al., 2011 [5] Sürder et al., 2013 [7] Subtotal (95% Cl) Table A ).
Study quality
All studies were assessed using the Juni criteria (Supplemental Table B ). All studies undertook adequate allocation and 79% of them provided detailed information about the method of randomization. Seven (29.2%) studies were double-blinded and 2 (8.3%) studies were single-blinded. Control patients did not undergo a sham biopsy and the infusion of cells in the other studies. Patient follow-up was completed in all studies. The percentage of patients lost to follow-up was acceptable.
Sensitivity analysis
The heterogeneity varied tremendously from low to high. The sensitivity analysis excluding 1 study at a time confirmed the results concerning all analyses in terms of direction and magnitude of statistical significance. The statistical heterogeneity(I 2 ) for LVEF vanished dramatically from 93% to 27%, indicating low heterogeneity among the majority of the studies included, except for the study by Wang et al. 2 Considering LVEF as the primary endpoint for almost all studies, this study was excluded in the following statistical analyses. After the exclusion, the heterogeneity for most cardiac parameters and all clinical outcomes was low.
Cardiac parameters and clinical outcomes
Only data with the longest duration of follow-up was referred to, although several follow-ups might have been conducted. Overall, BMCs transplantation to infarct-related region through the coronary artery was associated with statistically significant modification in all cardiac parameters (Table 1) .
Twenty-three out of 24 studies conducted a follow-up and provided a clinical outcome in the reports. However, Peto OR results indicated no improvement in clinical outcomes in the cell therapy arm compared with the control arm ( Table 2 ).
Subgroup analysis
Supplement of cell suspension
Many kinds of supplements were added to the final cell suspension such as serum, plasma, human serum albumin, phosphate-buffered saline, cell culture medium, etc. Whether serum or plasma was added was the only concern in this systematic review. Clinical trials which used serum/ plasma in the BMC suspension were compared with those that did not (Table 1) . No subgroup difference was found in the LVEF, LVESV and LVEDV (Supplemental Fig. 1-3) . However, statistic results indicated that cell suspension without serum/plasma tended to diminish the IS (-2.03%, p = 0.005), while the subgroup with the serum/plasma addition showed no impact on IS change (0.36%; p = 0.66). The difference between the 2 subgroups was statistically significant (p = 0.03) (Fig. 1) .
Although there were no significant differences in clinical outcomes, when all clinical trials included were considered, the analyses of subgroup differences showed that serum/plasma addition might increase all-cause mortality (Peto OR: 3.01; p = 0.06), which was significantly higher compared to non-serum/plasma subgroup (Peto OR: 0.47; p = 0.01) (Fig. 2) . No other subgroup differences were found to be significant in the other clinical outcomes ( Table 2) .
Anticoagulant usage
Thirteen out of 23 studies used heparin during cell preparation to prevent coagulation. The remaining studies used no anticoagulant during the procedure. Anticoagulant other than heparin was not found to be used in any study. When use of heparin and non-use of heparin was compared between the subgroups, IS change in the non-heparin subgroup was much greater than in the heparin subgroup (non-heparin vs heparin: -4.37% vs -0.75%; p = 0.03) (Fig. 3) . No significant subgroup difference was found in LVEF, LVESV and LVEDV (Supplemental Fig. 4-6 ). Clinical outcomes were also compared between the 2 subgroups and no subgroup difference was found, either.
Cell washout
Thirteen studies added heparin into BMCs for coagulation, and in 6 of them, BMCs were further washed out before the final cell suspension for infection was obtained. In the case of studies with heparin usage, all cardiac parameters were compared between the studies with the cell washout application and those without. No subgroup difference was found in the cardiac parameters (Supplemental Fig. 7-10 ). With regard to clinical outcomes, all-cause mortality was increased in the non-washout subgroup (Peto OR: 2.73; p = 0.06) and the intra-subgroup differences were significant (Peto OR: 2.73 vs 0.47; p = 0.04) (Fig. 4) .
Discussion
As far as we know, this is the first systematic review to focus on the impact of cell preparation on the efficacy and safety of intracoronary autologous BMCs transfer in patients with AMI. Firstly, this meta-analysis confirmed that, as compared with standard medical treatment, intracoronary BMCs therapy after AMI was associated with a significant increase in LVEF as well as a significant decrease in IS, LVESV and LVEDV, which indicated an improvement in left ventricular function and modification in remodeling. Meanwhile, subgroup analysis was performed to determine the effect of serum/plasma in intracoronary BMCs therapy. Unfortunately, less benefits in IS and higher all-cause mortality was observed in patients treated with serum/plasma suspended BMCs. Moreover, further subgroup analysis suggested that a more significant decrease of IS was observed in patients treated with non-heparinized intracoronary-admitted BMCs. In the studies using heparin for anticoagulation, all-cause mortality was reported to rise dramatically without the cell washout procedure, although cell washout could not impact the cardiac parameters.
To date, most of the available clinical trials of intracoronary BMCs transplantation result in significant yet modest improvements in LVEF, IS, LVESV and LVEDV, which was confirmed by the present study and other meta-analyses. 7, 31 Further studies indicated that the modest improvement of cardiac function after BMCs transplantation involves low cell survival and impaired cell with intracoronary application. 35 Notably, delayed clotting of the cell product was observed only in autologous serum from patients with anti-thrombotic therapy, but not from healthy donors or from patients without antithrombotic therapy. 35 In most clinical trials, the patients who received cell therapy were patients with AMI, routinely provided with anti-thrombotic therapy according to the current guidelines. In the presence of anti-thrombotic drugs, autologous serum was not sufficiently coagulated and induced spontaneous clotting of the final cell product. Therefore, when autologous serum is considered for cell suspension solution, especially for patients with anti-thrombotic therapy, serum preparation should be optimized in order to avoid subsequent clotting of the cell product. Utmost care has to be taken if autologous components are used.
Given that the intracoronary application of stem cells reduced the blood flow or even occluded arteries, probably by causing cell clotting, in some trials, anticoagulant agents like heparin were used during cell preparation with the intention to improve the therapeutic benefits of cell therapy in patients with AMI. 15, 26, 35 However, recently it has been indicated that the addition of heparin to stem cell suspension solution might interfere with the SDF-1/CXCR4 axis, thereby resulting in impaired migration and homing of BMCs. Hence, heparin was not recommended by the authors as an ideal anticoagulant. 36 There are earlier meta-analyses investigating the effect of heparin during cell preparation on LVEF and LVESV, but they arrived at conflict results. Jeevanantham et al. found that heparin in the final BMC suspension brought a greater improvement in LVEF and LVESV. 37 Contrarily, de Jong et al. suggested that the use of heparin during cell preparation did not seem to affect the therapy outcome. 31 The inconsistent results might be explained by the authors' different inclusion criteria regarding the cell type, the spectrum of disease and the route of injection. In this study, we focused on the therapeutic effect of BMCs in patients with AMI through an intracoronary infusion of BMCs. A subgroup analysis suggested that a more significant decrease of IS was observed in patients treated with non-heparinized intracoronaryadmitted BMCs. In the studies using heparin for anticoagulation, cell washout significantly lowered all-cause mortality, although this procedure could not impact the cardiac parameters. Since cell washout attenuates heparin and therefore diminishes its effect, it is reasonable to imply that heparin use for cell preparation might be useless or even harmful for the implantation of BMC in AMI patients, probably due to its interference with the SDF-1/CXCR4 axis. 36 Therefore, if anticoagulant agents are required to reduce potential cell clotting, we could deduce that the application of a new anticoagulant, like Bivalirudin, which does not interfere with the SDF-1/CXCR4 axis, should be of greater benefit for AMI patients undergoing cell therapy.
Conclusions and future perspective
Methodological differences in adult BMCs transplantation therapy have an impact on the cardiac parameters of patients suffering from an acute myocardial infarction. Non-use of serum or plasma in the cell suspension is associated with better performance in reducing the infarct area and lowering the risk of all-cause mortality. Meanwhile, heparin usage could diminish the benefit of infarct size reduction from BMCs therapy in AMI patients. In studies using heparin for anticoagulation, all-cause mortality rose dramatically without the cell washout procedure, although cell washout could not impact the cardiac parameters.
Further studies are needed to define the optimal components of cell suspension solution required for the maintenance of cell survival and activity. Instead of autologous medium supplements, the use of a combination of cytokines such as VEGF, IGF-1, HGF, SDF-1, PDGF and GCSF, which are known to improve cell activities, may be a preferred option. However, since our understanding and elaboration of the large amount of bioactive components within the serum are far from sufficient, further studies appear to be warranted to determine the optimal cocktail of factors that are required to maintain cell survival and bioactivities. Meanwhile, if new anticoagulant agents, such as Bivalirudin, Rivaroxiban, Apixaban, are required to reduce potential cell clotting, further systematic studies are needed to evaluate their effect on cell functions and long-term outcomes. 
Supplemental
